638 related articles for article (PubMed ID: 22586319)
1. The BATTLE trial: personalizing therapy for lung cancer.
Kim ES; Herbst RS; Wistuba II; Lee JJ; Blumenschein GR; Tsao A; Stewart DJ; Hicks ME; Erasmus J; Gupta S; Alden CM; Liu S; Tang X; Khuri FR; Tran HT; Johnson BE; Heymach JV; Mao L; Fossella F; Kies MS; Papadimitrakopoulou V; Davis SE; Lippman SM; Hong WK
Cancer Discov; 2011 Jun; 1(1):44-53. PubMed ID: 22586319
[TBL] [Abstract][Full Text] [Related]
2. A new BATTLE in the evolving war on cancer.
Sequist LV; Muzikansky A; Engelman JA
Cancer Discov; 2011 Jun; 1(1):14-6. PubMed ID: 22586313
[TBL] [Abstract][Full Text] [Related]
3. The BATTLE trial: a bold step toward improving the efficiency of biomarker-based drug development.
Rubin EH; Anderson KM; Gause CK
Cancer Discov; 2011 Jun; 1(1):17-20. PubMed ID: 22586314
[TBL] [Abstract][Full Text] [Related]
4. An overview of the design and conduct of the BATTLE trials.
Liu S; Lee JJ
Chin Clin Oncol; 2015 Sep; 4(3):33. PubMed ID: 26408300
[TBL] [Abstract][Full Text] [Related]
5. The BATTLE-2 Study: A Biomarker-Integrated Targeted Therapy Study in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer.
Papadimitrakopoulou V; Lee JJ; Wistuba II; Tsao AS; Fossella FV; Kalhor N; Gupta S; Byers LA; Izzo JG; Gettinger SN; Goldberg SB; Tang X; Miller VA; Skoulidis F; Gibbons DL; Shen L; Wei C; Diao L; Peng SA; Wang J; Tam AL; Coombes KR; Koo JS; Mauro DJ; Rubin EH; Heymach JV; Hong WK; Herbst RS
J Clin Oncol; 2016 Oct; 34(30):3638-3647. PubMed ID: 27480147
[TBL] [Abstract][Full Text] [Related]
6. Prospective molecular marker analyses of EGFR and KRAS from a randomized, placebo-controlled study of erlotinib maintenance therapy in advanced non-small-cell lung cancer.
Brugger W; Triller N; Blasinska-Morawiec M; Curescu S; Sakalauskas R; Manikhas GM; Mazieres J; Whittom R; Ward C; Mayne K; Trunzer K; Cappuzzo F
J Clin Oncol; 2011 Nov; 29(31):4113-20. PubMed ID: 21969500
[TBL] [Abstract][Full Text] [Related]
7. Randomized Phase II Trial of Seribantumab in Combination with Erlotinib in Patients with EGFR Wild-Type Non-Small Cell Lung Cancer.
Sequist LV; Gray JE; Harb WA; Lopez-Chavez A; Doebele RC; Modiano MR; Jackman DM; Baggstrom MQ; Atmaca A; Felip E; Provencio M; Cobo M; Adiwijaya B; Kuesters G; Kamoun WS; Andreas K; Pipas JM; Santillana S; Cho BC; Park K; Shepherd FA
Oncologist; 2019 Aug; 24(8):1095-1102. PubMed ID: 30975923
[TBL] [Abstract][Full Text] [Related]
8. Personalized therapy for non-small cell lung cancer: which drug for which patient?
Villaruz LC; Socinski MA
Semin Thorac Cardiovasc Surg; 2011; 23(4):281-90. PubMed ID: 22443647
[TBL] [Abstract][Full Text] [Related]
9. Biomarker analyses from a randomized, placebo-controlled, phase IIIb trial comparing bevacizumab with or without erlotinib as maintenance therapy for the treatment of advanced non-small-cell lung cancer (ATLAS).
Kabbinavar F; Fehrenbacher L; Hainsworth J; Kasubhai S; Kressel B; Marsland T; Patel T; Rubin M; White L; Yang JC; Klughammer B; Colburn D; Miller V; Johnson BE
J Thorac Oncol; 2014 Sep; 9(9):1411-7. PubMed ID: 25122437
[TBL] [Abstract][Full Text] [Related]
10. Bexarotene plus erlotinib suppress lung carcinogenesis independent of KRAS mutations in two clinical trials and transgenic models.
Dragnev KH; Ma T; Cyrus J; Galimberti F; Memoli V; Busch AM; Tsongalis GJ; Seltzer M; Johnstone D; Erkmen CP; Nugent W; Rigas JR; Liu X; Freemantle SJ; Kurie JM; Waxman S; Dmitrovsky E
Cancer Prev Res (Phila); 2011 Jun; 4(6):818-28. PubMed ID: 21636548
[TBL] [Abstract][Full Text] [Related]
11. Bayesian adaptive design for targeted therapy development in lung cancer--a step toward personalized medicine.
Zhou X; Liu S; Kim ES; Herbst RS; Lee JJ
Clin Trials; 2008; 5(3):181-93. PubMed ID: 18559407
[TBL] [Abstract][Full Text] [Related]
12. Current status of targeted therapy in non-small cell lung cancer.
Parums DV
Drugs Today (Barc); 2014 Jul; 50(7):503-25. PubMed ID: 25101332
[TBL] [Abstract][Full Text] [Related]
13. Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial.
Le Tourneau C; Delord JP; Gonçalves A; Gavoille C; Dubot C; Isambert N; Campone M; Trédan O; Massiani MA; Mauborgne C; Armanet S; Servant N; Bièche I; Bernard V; Gentien D; Jezequel P; Attignon V; Boyault S; Vincent-Salomon A; Servois V; Sablin MP; Kamal M; Paoletti X;
Lancet Oncol; 2015 Oct; 16(13):1324-34. PubMed ID: 26342236
[TBL] [Abstract][Full Text] [Related]
14. The BATTLE to personalize lung cancer prevention through reverse migration.
Gold KA; Kim ES; Lee JJ; Wistuba II; Farhangfar CJ; Hong WK
Cancer Prev Res (Phila); 2011 Jul; 4(7):962-72. PubMed ID: 21733820
[TBL] [Abstract][Full Text] [Related]
15. Precision Medicine in Lung Cancer Treatment.
Shah DR; Masters GA
Surg Oncol Clin N Am; 2020 Jan; 29(1):15-21. PubMed ID: 31757310
[TBL] [Abstract][Full Text] [Related]
16. [Personalized therapy of lung cancer - current standard and future challenges].
Riedel R; Wolf J
Dtsch Med Wochenschr; 2017 Nov; 142(22):1660-1668. PubMed ID: 29078211
[TBL] [Abstract][Full Text] [Related]
17. Personalized Therapy of Non-small Cell Lung Cancer (NSCLC).
Gadgeel SM
Adv Exp Med Biol; 2016; 890():203-22. PubMed ID: 26703806
[TBL] [Abstract][Full Text] [Related]
18. Targeted agents in the third-/fourth-line treatment of patients with advanced (stage III/IV) non-small cell lung cancer (NSCLC).
Langer CJ; Mok T; Postmus PE
Cancer Treat Rev; 2013 May; 39(3):252-60. PubMed ID: 22703830
[TBL] [Abstract][Full Text] [Related]
19. The role of molecular analyses in the era of personalized therapy for advanced NSCLC.
Tanner NT; Pastis NJ; Sherman C; Simon GR; Lewin D; Silvestri GA
Lung Cancer; 2012 May; 76(2):131-7. PubMed ID: 22176813
[TBL] [Abstract][Full Text] [Related]
20. A double-blind randomized discontinuation phase-II study of sorafenib (BAY 43-9006) in previously treated non-small-cell lung cancer patients: eastern cooperative oncology group study E2501.
Wakelee HA; Lee JW; Hanna NH; Traynor AM; Carbone DP; Schiller JH
J Thorac Oncol; 2012 Oct; 7(10):1574-82. PubMed ID: 22982658
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
